Kantarjian et al53 assessed the efficacy and protection of dasatinib, as as opposed with imatinib, for the main-line therapy of CML-CP. 5 hundred and nineteen clients with recently diagnosed CML-CP have been randomly assigned to get dasatinib at a dose of one hundred mg as soon as every day (259 https://morroniside99875.pointblog.net/detailed-notes-on-e-z-4-hydroxytamoxifen-69952344